{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:19:21Z","timestamp":1768029561818,"version":"3.49.0"},"reference-count":20,"publisher":"National Center for Global Health and Medicine (JST)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["GHM"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.35772\/ghm.2025.01104","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T22:08:29Z","timestamp":1765490909000},"page":"449-453","source":"Crossref","is-referenced-by-count":0,"title":["Optimization of cefepime dosage regimens for &lt;i&gt;Pseudomonas aeruginosa&lt;\/i&gt; infections in Japanese patients based on a pharmacokinetic\/pharmacodynamic analysis considering efficacy and safety: Is a 6 g daily dose and continuous infusion necessary?"],"prefix":"10.35772","volume":"7","author":[{"given":"Fumiya","family":"Ebihara","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Tokyo Women&apos;s Medical University Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kochi Medical School Hospital, Nankoku-shi, Kochi, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidefumi","family":"Kasai","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacometrics and Systems Pharmacology Keio Frontier Research and Education Collaboration Square (K-FRECS) at Tonomachi, Keio University, Kawasaki, Kanagawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Shiokawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokyo Women&apos;s Medical University Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"AMR Clinical Reference Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kochi Medical School Hospital, Nankoku-shi, Kochi, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21485","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Magill SS, O&apos;Leary E, Janelle SJ, <i>et al.<\/i> Changes in prevalence of health care-associated infections in U.S. hospitals. N Engl J Med. 2018; 379:1732-1744.","DOI":"10.1056\/NEJMoa1801550"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, Jones RN. The microbiology of bloodstream infection: 20-year trends from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 2019; 63:e00355-19.","DOI":"10.1128\/AAC.00355-19"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yano H, Hayashi W, Kawakami S, Aoki S, Anzai E, Zuo H, Kitamura N, Hirabayashi A, Kajihara T, Kayama S, Sugawara Y, Yahara K, Sugai M. Nationwide genome surveillance of carbapenem-resistant <i>Pseudomonas aeruginosa<\/i> in Japan. Antimicrob Agents Chemother. 2024; 68:e0166923.","DOI":"10.1128\/aac.01669-23"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA. Comparative review of the carbapenems. Drugs. 2007; 67:1027-1052.","DOI":"10.2165\/00003495-200767070-00006"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Craig WA. Pharmacokinetic\/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998; 26:1-10; quiz 11-12.","DOI":"10.1086\/516284"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: An update. J Antimicrob Chemother. 2005; 55:601-607.","DOI":"10.1093\/jac\/dki079"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009; 37:840-851; quiz 859.","DOI":"10.1097\/CCM.0b013e3181961bff"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Udy AA, Roberts JA, Lipman J. Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol. 2011; 7:539-543.","DOI":"10.1038\/nrneph.2011.92"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Shime N, Nakada T, Yatabe T, <i>et al.<\/i> The Japanese clinical practice guidelines for management of sepsis and septic shock 2024. J Intensive Care. 2025; 13:15.","DOI":"10.1186\/s40560-025-00819-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Huwyler T, Lenggenhager L, Abbas M, Ing Lorenzini K, Hughes S, Huttner B, Karmime A, U\u00e7kay I, von Dach E, Lescuyer P, Harbarth S, Huttner A. Cefepime plasma concentrations and clinical toxicity: A retrospective cohort study. Clin Microbiol Infect. 2017; 23:454-459.","DOI":"10.1016\/j.cmi.2017.01.005"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yamashita Y, Kamiyama H, Yamamoto A, Kanoh H, Yuhki Y, Ueda A, Kawamoto Y, Gotoh Y, Yamamoto S. Relationship between PK\/PD of cefepime and clinical outcome in febrile neutropenic patients with normal renal function. Yakugaku Zasshi. 2016; 136:1641-1649. (in Japanese)","DOI":"10.1248\/yakushi.16-00168"},{"key":"12","unstructured":"12. Yoshitsugu H, Sakurai T, Hiraoka M, Nakanomyo H. Adjustment of cefepime dosage in patients with renal impairment. Japanese Journal of Chemotherapy. 2005; 53:302-308. (in Japanese)"},{"key":"13","unstructured":"13. Sandoz Pharma K.K. Cefepime dihydrochloride for intravenous injection 0.5g (SANDOZ) \/ Cefepime dihydrochloride for intravenous injection 1g (SANDOZ). <i>https:\/\/www.info.pmda.go.jp\/go\/pack\/6132425D1032_1_07\/?view=frame&amp;style=XML&amp;lang=ja<\/i> (accessed September 1, 2025). (in Japanese)"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, Movahhed H, Tenney J, Martin RR. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother. 1992; 36:552-557.","DOI":"10.1128\/AAC.36.3.552"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nye KJ, Shi YG, Andrews JM, Wise R. Pharmacokinetics and tissue penetration of cefepime. J Antimicrob Chemother. 1989; 24:23-28.","DOI":"10.1093\/jac\/24.1.23"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010; 54:1111-1116.","DOI":"10.1128\/AAC.01183-09"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG, Fraser GL. Cefepime-induced neurotoxicity: A systematic review. Crit Care. 2017; 21:276.","DOI":"10.1186\/s13054-017-1856-1"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kalil AC, Metersky ML, Klompas M, <i>et al.<\/i> Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63:e61-e111.","DOI":"10.1093\/cid\/ciw353"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: A systematic review and meta-analysis. Lancet Infect Dis. 2007; 7:338-348.","DOI":"10.1016\/S1473-3099(07)70109-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Chapuis TM, Giannoni E, Majcherczyk PA, Chiol\u00e9ro R, Schaller MD, Berger MM, Bolay S, D\u00e9costerd LA, Bugnon D, Moreillon P. Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care. 2010; 14:R51.","DOI":"10.1186\/cc8941"}],"container-title":["Global Health &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/7\/6\/7_2025.01104\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:04:34Z","timestamp":1768017874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/7\/6\/7_2025.01104\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.35772\/ghm.2025.01104","relation":{},"ISSN":["2434-9186","2434-9194"],"issn-type":[{"value":"2434-9186","type":"print"},{"value":"2434-9194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"article-number":"2025.01104"}}